Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v12-EN Version v3-EN
Language English English
Date Updated 2020-04-22 2020-03-14
Drug Identification Number 02236564 02236564
Brand name LOVENOX WITH PRESERVATIVE 300MG/3ML LOVENOX WITH PRESERVATIVE 300MG/3ML
Common or Proper name Lovenox Multi Dose Vial Lovenox
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients ENOXAPARIN SODIUM ENOXAPARIN SODIUM
Strength(s) 100MG 100MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS
Packaging size 1 1
ATC code B01AB B01AB
ATC description ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2020-03-13 2020-03-13
Actual start date
Estimated end date 2020-04-24 2020-04-15
Actual end date 2020-04-21
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments API supply delay The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. API supply delay The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments